SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.

  • By

  • Andrea Surnit

  • June 9, 2026

  • 5 min

Share

  • 1

    SGLT2 inhibitors are associated with a lower incidence of kidney cancer compared to DPP-4 inhibitors in patients with type 2 diabetes.

  • 2

    The study involved 57,103 users of SGLT2 inhibitors and 57,103 users of DPP-4 inhibitors, with a follow-up of approximately 3.5 years.

  • 3

    SGLT2 inhibitor users had a 40% lower hazard of kidney cancer, with an incidence rate of 18.9 cases per 100,000 person-years.

  • 4

    The findings suggest potential mechanisms for reduced kidney cancer risk, but these were not directly tested in the study.

  • 5

    Limitations include observational design, short follow-up, and lack of individual agent data, affecting generalizability and potential confounding.

Original Source(s)

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

  • by Andrea Surnit

  • June 9, 2026

Related Content

Clinician Counseling and Weight Loss Attempts Among Survivors of Obesity-Associated Cancers

The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer

NHS-Galleri Linked to Delays

Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.